Tirzepatide 5mg not working: what's normal, what's not, and what happens next

What the SURMOUNT-1 data tell us about where 5mg sits in the journey

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised over 2,500 adults with obesity across 72 weeks. The headline figures (around 20–21% average body-weight reduction at the 15mg dose) came after a full titration sequence, not at the first therapeutic step. Participants did not arrive at those results quickly. Weight loss in the trial was cumulative and dose-dependent, meaning the body's response deepened as the dose increased and time passed.

At 5mg, you are two steps into a six-step schedule. The NHS tirzepatide medicines page describes the treatment as a titrated course where the prescriber adjusts the dose in stages, the starting and early doses exist partly to let your system adjust, and partly because the clinical effect accumulates over weeks. Feeling that nothing has changed after a few pens at 5mg is not unusual, but it is worth logging your data (weight, appetite, energy) rather than relying on memory.

If you want to understand how this dose sits within the broader mounjaro treatment picture, the 5mg dose overview covers what to expect at this specific step.

Reasons progress can genuinely slow at this dose, beyond the medicine itself

Tirzepatide works by reducing appetite and slowing gastric emptying, which leads most people to eat less without deliberate restriction. But the degree of response varies. Some people notice significant appetite suppression at 5mg; others feel relatively little until a higher dose. Both patterns appear in real-world use.

Outside the dose, several factors affect outcomes. Protein intake matters: lower-calorie eating that is short on protein accelerates muscle loss alongside fat, which can slow the rate of change on the scale. Disrupted sleep raises ghrelin (the hunger hormone) and can partly blunt the appetite suppression the medicine produces. Chronic stress has a similar effect. None of these are moral failings, they are physiological realities that your prescriber can discuss with you.

It is also worth being precise about timescales. If you have had two or three pens at 5mg and weighed yourself on different days of the week, at different times, the variation in readings can easily mask real progress. Weight fluctuates by one to three kilograms across a single week for most adults. Trend lines over four to six weeks are more informative than any single comparison. The 2.5mg not-working page covers early-dose expectations in more detail, which is useful context for understanding the pattern across the titration sequence, and if you are specifically concerned that 2.5mg Mounjaro did not seem to work for you, that resource looks at why the lowest dose can feel underwhelming and what it actually tells you about your likely response.

When slow progress at 5mg is a signal to speak to your prescriber

There is a clinical threshold that matters here. NICE's guidance on tirzepatide (TA1026) states that if a patient has not lost at least 5% of their body weight after six months at the highest tolerated dose, continuing the medicine should be reviewed. That threshold applies to the maintenance dose, not to 5mg, but the principle points to something important: outcome monitoring over time is the right measure, not a snapshot after a few weeks.

What does warrant a prescriber conversation sooner? If you have been on 5mg for the full recommended period and your prescriber has not yet discussed moving to 7.5mg, ask directly. If side effects are severe enough to affect your eating or daily life, that changes the picture. And if you are finding that 5mg Mounjaro does not seem to be working, a review of your full health picture (including any medicines that affect weight, thyroid function and sleep quality) is reasonable to request.

At nume, every repeat order goes back to a named prescriber for clinical review before dispatch. There is no auto-renewal. So if something is not working, that review is the right moment to say so, not after another month of waiting. Our clinical team reviews each case individually, and the conversation about whether to move to the next dose happens there, based on evidence rather than guesswork. For a wider look at how the full dose range works, the mounjaro overview is a useful reference.

What you should not do while waiting for things to change

The temptation to increase the dose yourself (taking the next pen early, or using two pens in a week) is understandable. It is also genuinely risky. Dose escalation outside the prescribed schedule can amplify side effects sharply, and there is no clinical cover for what happens next. The titration schedule exists because the gastrointestinal effects of tirzepatide are dose-dependent; going too fast too soon is the most common reason people stop treatment altogether.

Similarly, stopping without telling your prescriber removes the safety check that should precede any change. If cost is a factor in the decision, our Mounjaro pricing page explains what is included in a single transparent price, because the affordability question is often worth raising before stopping. People sometimes get to the end of a Thursday evening feeling like nothing is happening and cancel before Friday's weigh-in tells a different story.

If you are not yet a patient and are trying to understand whether tirzepatide might be suitable for you, the weight-loss treatment overview covers eligibility and what the private route involves. A full clinical assessment is the right starting point. You can check your eligibility through a free consultation, no commitment, no fee, and a real prescriber reads your answers the same day.